Outcomes and predictors of efficacy of palliative radiotherapy in patients with malignant pleural mesothelioma

Not Applicable

• Conditions: malignant pleural mesothelioma; Cancer - Lung - Mesothelioma

• Registration Number: ACTRN12614001265662
• Lead Sponsor: Sir Charles Gairdner Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-12-03
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Patients with histologically or cytologically confirmed malignant pleural mesothelioma (MPM
Patients with focal clinical symptoms likely to be caused by MPM as confirmed by prior imaging imaging (including non-pleural metastatic disease)
Clinical indication to undergo palliative radiotherapy in the opinion of the treating physician
Able to undergo study procedures
More than 6 weeks post radiotherapy (at the time of the PET scan)
More than 6 weeks post chemotherapy or surgery (at the time of the PET scan), or 3 weeks is acceptable if disease has progressed on most recent chemotherapy.
Able to undergo study procedures
Lesion/s to be treated is/are radiologically measurable as per modified RECIST or RECIST
Baseline pain score on VAS greater than or equal to 4 AND/OR MED is greater or equal to 10mg/24 hours

Exclusion Criteria

Currently receiving chemotherapy or radiotherapy
Radiotherapy to same site
Intention to commence chemotherapy < 6 weeks post radiotherapy
Pregnant or breastfeeding at the time of study enrolment
Unable to provide signed informed consent
Inadequate English language to complete study outcome measures
Medical contraindication to palliative radiotherapy
Geographically inaccessible for follow-up
Less than 18 years of age

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of participants with a symptomatic response to radiotherapy at 6 weeks post treatment, as measured by a visual analogue pain score using the VAS numeric pain distress scale. Analgesic use measured by a patient medication questionnaire.<br> <br>[6 weeks post radiotherapy treatment]